The global outpatient oncology infusion market size is calculated at USD 96.77 billion in 2025 and is forecasted to reach around USD 244.03 billion by 2034, accelerating at a CAGR of 10.84% from 2025 to 2034. The North America outpatient oncology infusion market size surpassed USD 31.38 billion in 2024 and is expanding at a CAGR of 11% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Outpatient Oncology Infusion Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Outpatient Oncology Infusion Market, by Product
8.1.1. Infusion Pumps
8.1.1.1. Market Revenue and Forecast
8.1.2. Intravenous Sets
8.1.2.1. Market Revenue and Forecast
8.1.3. IV Cannulas
8.1.3.1. Market Revenue and Forecast
8.1.4. Needleless Connectors
8.1.4.1. Market Revenue and Forecast
9.1. Outpatient Oncology Infusion Market, by Application
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast
9.1.4. Prostate Cancer
9.1.4.1. Market Revenue and Forecast
10.1. Outpatient Oncology Infusion Market, by Therapy
10.1.1. Chemotherapy
10.1.1.1. Market Revenue and Forecast
10.1.2. Targeted Therapy
10.1.2.1. Market Revenue and Forecast
10.1.3. Immunotherapy
10.1.3.1. Market Revenue and Forecast
10.1.4. Hormonal Therapy
10.1.4.1. Market Revenue and Forecast
11.1. Outpatient Oncology Infusion Market, by Mode
11.1.1. Intramuscular (IM)
11.1.1.1. Market Revenue and Forecast
11.1.2. Intravenous (IV)
11.1.2.1. Market Revenue and Forecast
11.1.3. Subcutaneous
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Therapy
12.1.4. Market Revenue and Forecast, by Mode
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Therapy
12.1.5.4. Market Revenue and Forecast, by Mode
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Therapy
12.1.6.4. Market Revenue and Forecast, by Mode
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Therapy
12.2.4. Market Revenue and Forecast, by Mode
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Therapy
12.2.5.4. Market Revenue and Forecast, by Mode
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Therapy
12.2.6.4. Market Revenue and Forecast, by Mode
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Therapy
12.2.7.4. Market Revenue and Forecast, by Mode
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Therapy
12.2.8.4. Market Revenue and Forecast, by Mode
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Therapy
12.3.4. Market Revenue and Forecast, by Mode
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Therapy
12.3.5.4. Market Revenue and Forecast, by Mode
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Therapy
12.3.6.4. Market Revenue and Forecast, by Mode
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Therapy
12.3.7.4. Market Revenue and Forecast, by Mode
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Therapy
12.3.8.4. Market Revenue and Forecast, by Mode
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Therapy
12.4.4. Market Revenue and Forecast, by Mode
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Therapy
12.4.5.4. Market Revenue and Forecast, by Mode
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Therapy
12.4.6.4. Market Revenue and Forecast, by Mode
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Therapy
12.4.7.4. Market Revenue and Forecast, by Mode
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Therapy
12.4.8.4. Market Revenue and Forecast, by Mode
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Therapy
12.5.4. Market Revenue and Forecast, by Mode
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Therapy
12.5.5.4. Market Revenue and Forecast, by Mode
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Therapy
12.5.6.4. Market Revenue and Forecast, by Mode
13.1. B. Braun Melsungen AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Baxter
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Becton
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Dickinson and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Fresenius Kabi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICU Medical, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. IRadimed Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Nipro Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Terumo Corporation.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Smith's Medical
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample